Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311,… byPallavi MadhirajuMay 21, 2024